A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques
| Autor: | John H. Eldridge, George N. Pavlakis, Shakuntala Megati, Vidia Roopchand, Priscilla Piacente, Barbara K. Felber, Jorge Quiroz, David B. Weiner, Zimra R. Israel, Sarah Cappello, Eva B. Schadeck, Dorys Garcia-Hand, Maninder K. Sidhu, Siew-Yen Chong, Jean D. Boyer, Michael A. Egan, Amjed Masood |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Vaccination schedule
viruses animal diseases medicine.medical_treatment Gene Products gag Enzyme-Linked Immunosorbent Assay Biology medicine.disease_cause Antibodies Viral Immune system Adjuvants Immunologic Immunopathology medicine Vaccines DNA Animals Immunity Cellular General Veterinary General Immunology and Microbiology ELISPOT Public Health Environmental and Occupational Health Simian immunodeficiency virus Virology Interleukin-12 Macaca mulatta Vaccination Infectious Diseases Cytokine Immunology Molecular Medicine Simian Immunodeficiency Virus Adjuvant Plasmids |
| Zdroj: | Vaccine. 24(21) |
| ISSN: | 0264-410X |
| Popis: | An experimental pDNA vaccine adjuvant expressing IL-12 was evaluated for its ability to augment the humoral and cellular immune responses elicited by a SIVmac239 gag p39 expressing pDNA vaccine. To determine the effect of vaccine dose on the immune response, rhesus macaques were immunized with 1.5 mg or 5.0 mg of SIVmac239 gag pDNA, with or without co-immunization of IL-12 pDNA at 1.5 mg and 5.0 mg, respectively. Serum antibody responses to simian immunodeficiency virus (SIV) gag were increased 10-fold ( p = 0.044, 0.002) in macaques receiving IL-12 pDNA. Cellular immune responses, monitored by SIV gag-specific IFN-γ ELISpot assay, were also significantly higher ( p = 0.007, 0.019) when the pDNA vaccine was co-immunized with IL-12 pDNA at high and low doses. There was no statistical difference between the immune responses elicited by the high and low dose of IL-12 pDNA ( p = 0.221, 0.917), a finding which could allow a dose reduction of vaccine without the concomitant loss of imunogenicity. Furthermore, analysis of the breadth of the T-cell response during the vaccination schedule, using overlapping peptides to SIV gag, demonstrated a significant correlation ( p = 0.0002) between the magnitude and breadth of the immune responses in the vaccines. These results have important implications for the continuing development of an effective, safe low dose pDNA vaccine adjuvant suitable for human use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect